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Comparison of Costs of Endovascular Repair versus Open 
Surgical Repair for Abdominal Aortic Aneurysm in Korea
This study was designed to compare the hospital-related costs of elective abdominal aortic 
aneurysm (AAA) treatment and cost structure between endovascular aneurysm repair 
(EVAR) and open surgical repair (OSR) in Korean health care system. One hundred five 
primary elective AAA repairs (79 OSRs and 26 EVARs) performed in the Seoul National 
University Hospital from 2005 to 2009 were included. Patient characteristics were similar 
between two groups except for older age (P = 0.004) and more frequent history of 
malignancy (P = 0.031) in EVAR group. Thirty-day mortality rate was similar between two 
groups and there was no AAA-related mortality in both groups for 5 yr after repair. The 
total in-hospital costs for the index admission were significantly higher in EVAR patients 
(mean, KRW19,857,119) than OSR patients (mean KRW12,395,507) (P < 0.001). The 
reimbursement was also significantly higher in EVAR patients than OSR patients (mean, 
KRW14,071,081 vs KRW6,238,895, P < 0.001) while patients payments was comparable 
between two groups. EVAR patients showed higher follow-up cost up to 2 yr due to more 
frequent imaging studies and reinterventions for type II endoleaks (15.4%). In the 
perspective of cost-effectiveness, this study suggests that the determination of which 
method to be used in AAA treatment be more finely trimmed and be individualized.
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INTRODUCTION
Abdominal aortic aneurysm (AAA) is a life-threatening disease 
when rupture occurs. Elective open surgical repair (OSR) has 
been the optimal therapy to prevent AAA rupture. However, after 
the first introduction by Parodi et al. (1), endovascular aneurysm 
repair (EVAR) has increased dramatically and is the most popu-
lar therapy nowadays (2). A number of studies reported that 
EVAR has significant benefit over OSR in terms of rapid postop-
erative recovery, fewer intensive care unit administration and 
reduction in hospital stay (3, 4). These benefits might result in 
reduced hospital costs for AAA repair. Early studies reported 
that EVAR was associated with lower hospital cost (5). However, 
this initial advantage in cost is gradually disappearing in the long-
term after EVAR due to more frequent life-long follow-up imag-
ing and higher reintervention rates. Some recent studies have 
reported even similar or higher hospital costs for EVAR (4, 6-10). 
  The cost-effectiveness of a new medical therapy can vary ac-
cording to the medical insurance system in each nation. Although 
some studies from western countries have dealt with cost-effec-
tiveness of EVAR in the management of AAA, these results can-
not be applied directly to Korea. To justify the routine use of EVAR 
for AAA treatment in Korea, it is needed to prove the cost-effec-
tiveness under the current situation of reimbursement and pa-
tient payment of the National Health Insurance (NHI) Corpora-
tion. Health care costs can affect clinical decision making but 
also the policy of the National Health Insurance program. Until 
recently, however, no studies regarding cost-effectiveness of 
EVAR is conducted in Korea. Therefore the aim of this study was 
to compare the hospital-related cost of elective AAA treatment 
including peri- and post-operative costs and to study cost struc-
ture between those selected for open or endovascular repair.
MATERIALS AND METHODS
Between January 2005 and December 2009, 120 infrarenal AAA 
repairs were performed in Seoul National University Hospital. 
Among them, 15 operations were excluded from the study due 
to various reasons, including 9 ruptured aneurysms, 2 stent graft 
migrations, 1 foreign patient, and 3 complicated AAAs such as 
infected aneurysm. The remaining 105 primary elective AAA 
repairs (79 OSRs and 26 EVARs) were included in this study. 
  Patients were generally admitted 3 or 4 days before OSR or 
EVAR. The decision to choose the repair method was based on Min SI, et al.  •  Cost Comparison of Endovascular or Open Aneurysm Repair in Korea
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the anatomic configuration of the aneurysm, patient comorbid-
ities, and patient preference with surgeon’s recommendation. 
OSR was performed through midline (n = 70) or retroperitoneal 
(n = 9) approach and a Dacron (DuPont, Wilmington, DE, UAS) 
graft was implanted. EVAR was performed using bilateral femo-
ral cutdown under general anesthesia. Zenith (Cook, Blooming-
ton, IN, USA; n = 22) or Excluder (W.L. Gore & Associates, Flag-
staff, AZ, USA; n = 4) were placed. For follow-up, patients treat-
ed with EVAR were routinely checked with computed tomogra-
phy (CT) angiography at 1, 6, and 12 months after surgery and 
annually thereafter with clinical examination at each hospital 
visit. The standard follow-up program of OSR patients consisted 
of clinical examination at 1, 6, and 12 months after surgery and 
annually thereafter.
  Medical records were reviewed to obtain patients character-
istics, preoperative investigations, operative details, early and 
late complications, the need for additional procedures, the length 
of stay in the intensive care unit (ICU) and hospital, and out-
come parameters as defined by the Ad Hoc Committee for Stan-
dardized Reporting Practices in Vascular Surgery (11). Addition-
al data on survival for patients with loss to follow-up were ob-
tained from the Electronic Data for Resident Registration of the 
Ministry of Public Administration and Security, Korean Govern-
ment and by telephone survey.
  All hospital-related costs linked to AAA treatment were in-
cluded in the cost analysis. The cost for each patient was deter-
mined by accessing the hospital cost accounting system which 
includes detailed data on operations, anesthesia, pre- and post-
operative investigations, intensive care, and postoperative hos-
pitalization. The total hospital cost for the index admission was 
divided into preoperative costs, operative costs, and postopera-
tive costs including costs for ICU stay and hospital stay. Follow-
up costs linked to AAA treatment were obtained from discharge 
until July 2010. 
  Preoperative cost was determined as costs incurred by all in-
vestigations and hospitalization performed preoperatively after 
the decision for aneurysm repair was made. Therefore, preop-
erative costs included cost of CT angiography, cardiorespiratory 
investigations, consultations, medications, clinical laboratory 
costs, bed costs and interventions performed during hospital 
admission. Operative costs included graft costs, operation charg-
es, anesthesia charges, medications, and additional costs for 
guidewires, catheters, sheath, and contrast used during EVAR. 
Postoperative cost was defined as the sum of costs incurred by 
postoperative ICU stay and all cost after returning to the general 
ward until discharge such as bed and nursing costs, medical 
imaging, consultations, medications, clinical laboratory costs, 
and additional interventions. Follow-up costs included all AAA 
treatment-related costs after discharge such as routine follow-
up costs, CT angiography, additional interventions required to 
treat endoleaks and rehospitalization. 
  Statistical outliers (OSR, n = 2; EVAR, n = 1) of more than 3 
standard deviations from the mean for total hospital costs dur-
ing the main admission were excluded from the cost analysis (12).     
  In Korea, total hospital costs are divided into benefit-service 
charges of which 80% are reimbursed by the NHI Corporation, 
and nonbenefit-service charges. Patients pay 20% of the benefit 
services and all nonbenefit-service charges. Thus, total hospital 
cost, reimbursement by NHI Corporation and patient payment 
were calculated for each patient and compared between OSR 
and EVAR patients.
  Statistical analyses were conducted using SPSS software, ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). The data were expressed 
as means ± standard deviation values or as frequencies (per-
centages), according to the data type. For data which did not fit 
normal distribution, medians were reported with interquartile 
range and compared with Wilcoxon rank sum test. Mean values 
were compared by Mann-Whitney U test for continuous vari-
ables. Noncontinuous variables were compared by chi-squared 
test. Patient survival rates were determined by Kaplan-Meier 
analysis and log-rank method. A P value  < 0.05 was considered 
statistically significant. All costs and charges were expressed in 
Korean won (KRW).
Ethics statement
This study was performed after obtaining approval from the in-
stitutional review board of Seoul National University Hospital  
(IRB No. H-1006-005-319). This study was waived of informed 
consent from the board.
RESULTS
Patient characteristics
During the study period, 79 patients underwent OSR and 26 pa-
tients underwent EVAR as primary elective treatment for AAA. 
The baseline clinical characteristics of the patients in the two 
groups are shown in Table 1. The mean age of the patients in 
the EVAR group was higher than the OSR group (75.0 ± 8.1 vs 
70.3 ± 8.0, P = 0.004), and combined malignant disease was 
more frequent in the EVAR group compared to the OSR group 
(30.8% vs 11.4%, P = 0.031). There was no significant difference 
between the groups with regard to other clinical characteristics 
examined.
  The anatomical characteristics of AAA were quite similar be-
tween the two groups. The mean diameter of the aneurysms 
were 58.5 ± 10.6 mm in the OSR group and 57.2 ± 8.6 mm in the 
EVAR group (P = 0.563). There was no difference in the length 
of proximal neck (26.8 ± 14.9 mm in the OSR group vs 27.9 ± 9.8 
mm in the EVAR group, P = 0.727) between the two groups and 
more than two third of the patients showed aneurysmal involve-
ment of common iliac artery in both groups (P = 0.607).  Min SI, et al.  •  Cost Comparison of Endovascular or Open Aneurysm Repair in Korea
418   http://jkms.org http://dx.doi.org/10.3346/jkms.2012.27.4.416
Postoperative complications and clinical outcome
Both OSR and EVAR groups had a low morbidity. The perioper-
ative and postoperative complications are listed in Table 2. EVAR 
resulted in a tendency for a reduced length of hospital stay as 
well as length of ICU stay. The median length of postoperative 
hospital stay was 8 days in the EVAR group (range, 7-14.5 days) 
and was 10 days in the OSR group (range, 8-14 days; P = 0.078). 
All patients except one in the EVAR group went to the ICU post-
operatively but there appeared to be a shorter length of ICU stay 
in the EVAR group, with a median ICU stay of 1 day (range, 1-2 
days) in the EVAR group compared with 2 days (range, 1-2 
days) in the OSR group (P = 0.110).
  There was no significant difference in 30-day mortality be-
tween the groups (2.5% for OSR vs 4.0% for EVAR, P = 0.566). 
Causes of 3 inhospital mortalities were sepsis in 2 patients and 
subdural hemorrhage in an other patient. Although 5-yr patient 
survival was significantly inferior in the EVAR group compared 
to OSR group (54.5% vs 91.9%, P < 0.001), there was no AAA-re-
lated mortality in both groups. The causes of patient death were 
malignant disease, sepsis, acute myocardiac infarction, fall down 
accident, and intracranial hemorrhage (Fig. 1). With regard to 
the frequencies of postoperative interventions during the index 
admission, there were no differences between the two groups 
(Table 3). Four patients (5.1%) in the OSR group and 3 patients 
(11.5%) in the EVAR group required reoperation (P = 0.361). 
One patient from the EVAR group underwent OSR because of 
persistent type I endoleak at 7 days after EVAR. The EVAR group 
showed significantly higher rate of type II endoleak (34.6%) and 
need for intervention of type II endoleak (15.4%, P < 0.001), with 
a mean follow up duration of 888 ± 548 days in the OSR group 
Table 1. Demographics and clinical characteristics of patients undergoing OSR and EVAR
Characteristics  Overall (n = 105) OSR (n = 79) EVAR (n = 26) P value
Male gender, No. (%)    92 (87.6)  68 (86.1)  24 (92.3) 0.510
Age (yr) 71.7 ± 8.3 70.3 ± 8.0 75.9 ± 8.1 0.004
Body Mass Index (kg/m
2) 23.6 ± 4.0 23.6 ± 4.2 23.9 ± 3.3 0.610
Medical comorbidities
   Cardiac disease, No. (%)
   Cerebrovascular disease, No. (%) 
   Carotid disease, No. (%)
   COPD, No. (%)
   Current smoker, No. (%) 
   Previous smoker, No. (%) 
   Hypertension, No. (%) 
   Diabetes, No. (%) 
   Dyslipidemia, No. (%) 
   Chronic renal disease, No. (%) 
   Cancer, No. (%) 
   Previous vascular disease, No. (%) 
 
  32 (30.5)
  16 (15.2)
  8 (7.6)
  20 (19.0)
  33 (31.4)
  40 (38.1)
  79 (75.2)
10 (9.5)
  18 (17.1)
  9 (8.6)
  17 (16.2)
  6 (5.7)
 
21 (26.9)
13 (16.5)
7 (8.9)
14 (17.7)
25 (31.6)
29 (36.7)
60 (75.9)
5 (6.3)
13 (16.5)
7 (9.0)
  9 (11.4)
6 (7.6)
 
11 (42.3)
  3 (11.5)
1 (3.8)
  6 (23.1)
  8 (30.8)
11 (42.3)
19 (73.1)
  5 (19.2)
  5 (19.2)
2 (7.7)
  8 (30.8)
0 (0.0)
 
0.219
0.755
0.676
0.571
0.933
0.646
0.796
0.065
0.768
0.840
0.031
0.330
OSR, open surgical repair; EVAR, endovascular aneurysm repair; COPD, chronic obstructive pulmonary disease.
Table 2. Peri- and post-operative morbidities 
Characteristics 
OSR  
(n = 79) 
EVAR  
(n = 26) 
P value 
Transfusion, No. (%) of cases 27 (34.6)    8 (30.8)  0.813 
Bleeding requiring intervention, 
   No. (%) of cases 
2 (2.6)  0 (0.0)  1.000 
Thromboembolic, either artery or vein, 
   No. (%) of cases 
2 (2.6)  1 (3.8)  1.000 
Bowel ischemia, No. (%) of cases  0  0 
Buttock claudication, No. (%) of cases 1 (1.3)  0 (0.0)  1.000 
Acute myocardial infaction, 
   No. (%) of cases
2 (2.6)  0 (0.0)  1.000 
Acute renal failure, No. (%) of cases 1 (1.3)  1 (3.8)  1.000 
Cerebrovascular accident, 
   No. (%) of cases
1 (1.3)  1 (3.8)  1.000 
Pneumonia, No. (%) of cases 4 (5.1)  1 (3.8)  1.000 
Sepsis, No. (%) of cases 1 (1.3)  2 (7.7)  0.153 
In-hospital mortality, No. (%) of cases 2 (2.5)  1 (4.0)  0.566 
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P < 0.001 (log rank)
EVAR
OSR
0  12  24  36  48  60
1.0
0.8
0.6
0.4
0.2
0.0
Cause of death OSR   EVAR
Cancer, No. (%) 2 (2.5)   4 (15.4)
Sepsis, No. (%) 1 (0.1) 2 (7.7)
Accident, No. (%) 1 (0.1) 0 (0.0) 
AMI, No. (%) 0 (0.0) 1 (3.9)
ICH, No. (%) 0 (0.0) 1 (3.9)
Unknown 0 (0.0) 1 (3.9)
Fig. 1. Patient survival and the causes of death in both groups. OSR, open surgical 
repair; EVAR, endovascular repair; AMI, acute myocardial infarction; ICH, intracranial 
hemorrhage.Min SI, et al.  •  Cost Comparison of Endovascular or Open Aneurysm Repair in Korea
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and 576 ± 473 days in the EVAR group.
 
Costs
Figs. 2 and 3 display the cost structure of both treatment groups. 
Operative costs comprised a large proportion of total hospital 
costs. Operative cost was significantly higher in the EVAR group 
compared to the OSR group, which was mainly attributed by the 
high cost of endografts and disposables such as sheaths and 
guidewires (Fig. 2). Therefore total hospital costs (KRW19,857,119.2 
± 5,909,556.0 vs KRW12,395,507.6 ± 6,788,119.2, P < 0.001) were 
significantly higher in EVAR patients compared to the OSR group. 
Because of the reimbursement of the endo-graft by the NHI 
Corporation, patient payment was comparable between two 
groups (KRW6,156,612.5 ± 3,931,410.6 for OSR vs KRW5,786,037.8 
± 1,684,082.5 for EVAR, P = 0.380) while the reimbursement  
by NHI Corporation was significantly higher in EVAR group 
(KRW 6,238,895.1 ± 3,393,210.0 for OSR vs KRW14,071,081.4 ±  
4,856,932.5 for EVAR, P < 0.001) (Fig. 3). 
  When the total hospital costs incurred during the index ad-
mission were divided into three stages, the preoperative and 
postoperative costs were similar in both groups. The mean pre-
operative costs (Fig. 2A) including consultation, cardiorespira-
tory investigations, imaging studies, clinical laboratory costs and 
bed costs (KRW2,532,484 ± 1,652,591 for OSR vs KRW2,037,121 
± 1,876,712 for EVAR, P = 0.255) were similar. Furthermore, the 
mean postoperative costs (Fig. 2B) including ICU care and post-
Table 3. Postoperative reinterventions
Interventions
OSR  
(n = 79) 
EVAR  
(n = 26) 
P value 
Reoperation, No. (%) 
   Bleeding control, No. (%) 
   Wound repair, No. (%) 
   Endoleak, type I, No. (%) 
   Embolectomy, No. (%) 
4 (5.1) 
2 (2.5) 
2 (2.5) 
0 (0.0) 
0 (0.0) 
3 (11.5) 
0 (0.0) 
1 (3.8) 
1 (3.8) 
1 (3.8) 
0.361 
1.000 
1.000 
0.248 
0.248 
Immediate intervention, No. (%) 
   Wmbolization for bleeder, No. (%) 
   Aspiration thrombectomy, No. (%) 
   Embolization for type II endoleak 
2 (2.5) 
1 (1.3) 
1 (1.3) 
0 (0.0) 
1 (3.8) 
0 (0.0) 
0 (0.0) 
1 (3.8) 
1.000 
1.000 
1.000 
0.248 
Follow-up 
   Mean f/u duration, days 
   Type II endoleak, No. (%) 
   Intervention for type II endoleak, 
      No. (%) 
 
888 ± 548 
0 
0 
 
576 ± 473 
9 (34.6) 
4 (15.4) 
0.007 
< 0.001 
0.003 
OSR   EVAR P value
Disposables KRW318,306.4 KRW1,296,660.4 < 0.001
Implants KRW723,065.7 KRW9,021,037.3 < 0.001
Anesthesia KRW620,620.2 KRW436,734.3 < 0.001
Operation KRW172,837.5 KRW733,165.9 < 0.001
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Fig. 2. Cost structures for OSR and EVAR. (A) Preoperative costs, (B) Postoperative 
costs including costs for ICU stay, and (C) cost for procedure per se. OSR, open surgi-
cal repair; EVAR, endovascular repair.
Fig. 3. Cost structure in OSR and EVAR group during the index admission. (A) total hospital cost, (B) patient payments and (C) NHI reimbursement. OSR, open surgical repair; 
EVAR, endovascular repair; NHI, National Health Insurance.
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operative ward admission (KRW4,823,165.8 ± 2,813,945.4 vs 
KRW4,850,649.2 ± 2,807,148.9, respectively for EVAR and OSR 
group, P = 0.968) were similar. The length of postoperative ICU 
and hospital stay tended to be shorter in the EVAR group, how-
ever it could not induce economic advantage nor offset the cost 
of endo-graft (Fig. 2). 
  During the postoperative follow-up, patients in the EVAR 
group were routinely checked with CT angiogram at 1, 6, and 
12 months after surgery. Four (15.4%) out of 9 (34.6%) patients 
with type II endoleak were treated with additional intervention. 
No patient required conversion to OSR. At 1 yr follow-up, the 
EVAR group required significantly higher cost than the OSR 
group (KRW648,538.1 ± 926,975.6 vs KRW180,844.8 ± 189,659.1, 
P < 0.001) and the discrepancy in the cumulative cost increased 
further till 2 yr follow-up (KRW1,612,226 ± 1,319,305.8 vs KRW 
393,203.8 ± 356,785.8 respectively, P < 0.001).   
DISCUSSION
The number of patients with AAA is rapidly increasing in Korea 
and, after the inception of reimbursement for endo-grafts by 
the Health Insurance Reimbursement Association (HIRA), EVAR 
has become the preferred method for AAA treatment, replacing 
OSR (13). Health economic evaluation for a new treatment strat-
egy should be mandatory before it is reimbursed within the health 
service system and a number of reports on cost-effectiveness of 
EVAR have been published in western countries (5-10, 14-23). 
However, this issue of cost-effectiveness of EVAR has never been 
evaluated in the Korean health care system.     
  The principal finding of this study is that the total in-hospital 
costs for EVAR (KRW19,857,119.2) were significantly higher than 
those for OSR (KRW12,395,507.6), which contrasted with sever-
al reports from Western countries that showed EVAR was less 
costly or equal in cost to OSR (10, 19). The most important cause 
for the difference in total in-hospital costs between EVAR and 
OSR was the cost of the procedures themselves. Although there 
were reductions in anesthesia and operation fee in the EVAR 
group, this could not recoup the high costs of the endovascular 
graft (KRW9,021,037.3) and disposables (KRW1,296,660.4) such 
as guidewires, sheaths and radiocontrast materials (Fig. 2). This 
is mainly due to the lower costs of operation-related fees in Korea, 
while higher operation fees in western countries recoup the en-
dograft costs. In addition, almost every patient in the EVAR group 
in this study was admitted to the ICU and the length of hospital 
stay was also comparable between the two study groups. This 
might be caused by the treatment policy of the vascular surgery 
team in the study hospital. However, this reduction in hospital 
and ICU stay cannot offset the costs of the endovascular grafts, 
because the mean cost of the endografts accounted for 45.4% of 
the total in-hospital cost in the EVAR group and the mean cost 
of postoperative ICU and hospital stay accounted for only 24.3%. 
Furthermore, this study showed that 2-yr cumulative follow-up 
costs were also higher for EVAR than OSR (Fig. 4), which is sim-
ilar to the western studies. Because CT was regularly checked to 
identify endoleaks, graft migration, graft kinking or other com-
plications related to EVAR and secondary intervention was ad-
ditionally required in some cases, follow-up costs increase cost 
disparity after EVAR (4, 8, 17).
  Another interesting finding in this study was that patient pay-
ments were not different between EVAR (KRW5,786,037.8) and 
OSR (KRW6,156,612.5) patients. This was caused by the reim-
bursement off higher cost materials including endovascular 
grafts and disposables by the HIRA which accounted for the 
largest portion of the costs in EVAR, the amount of reimburse-
ment by NHI Corporation reaching KRW14,071,081.4. There-
fore, as the number of patients undergoing EVAR increases, the 
financial burden of the NHI Corporation is becoming more 
considerable. This issue should be discussed for the proper dis-
tribution of the national health resources.
  Three randomized trials comparing EVAR and OSR have all 
shown a markedly reduced 30-day operative mortality for EVAR 
and this benefit has made EVAR a more prevalent treatment 
option (3, 4, 24). This study also revealed the safety of EVAR with 
limited follow-up period. No AAA-related deaths occurred in 
both groups (Fig. 1). However, considering the recent EVAR1 
trial by Greenhalgh et al. (8), longer-term follow-up analysis 
showed increased rates of endograft-related complications in-
cluding type II endoleaks and additional interventions in the 
EVAR group. In contrast to EVAR, OSR has strong evidence re-
garding durability (25, 26) and no graft-related complications 
occurred in this study population. Overall, current evidence in-
cluding this study show that EVAR has early advantage in terms 
of operation-related mortality and morbidity but is associated 
with significantly higher graft cost which is not offset by short 
stay in ICU or hospital, higher graft-related complications and 
reintervention resulting in higher follow-up costs. 
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  It is noteworthy that new graft-related complications can de-
velop and the need for reintervention persists even at 8 yr after 
EVAR (8). Considering the continued evaluation with CT for 
graft-related complications, EVAR may prove to be cost-effec-
tive only in very elderly patients. It is clear that, although EVAR 
showed lower operative mortality, careful follow-up after EVAR 
is also mandatory. Therefore costs for EVAR procedure and for 
follow-up are significantly higher. In addition, EVAR patients 
are potentially exposed to a significant cumulative amount of 
iatrogenic radiation from pre-operative assessment to death by 
life-long follow-up of CT angiography, with the associated car-
cinogenic risks (27). In this regard it is doubtful whether EVAR 
routinely offered even to relatively young patients with low op-
erative risks. The eventual impact of the radiation dose by EVAR 
and life-long check up of CT is more pertinent in younger pa-
tients requiring aneurysm repair, potentially exposing these pa-
tients to carcinogenic risk with a latency period of between 10 
and 20 yr. Therefore, the decision of which method to be used 
in AAA treatment should be individualized (28). All patients 
should be informed of the advantages and disadvantages of 
EVAR and OSR. Medical practitioners should balance the pa-
tient’s operative risks and disadvantages of EVAR. 
  Summarizing, the total in-hospital costs for EVAR are signifi-
cantly higher than those for OSR. A lower number of days of 
hospital admission and ICU care cannot offset higher proce-
dural costs for EVAR. This study suggests “EVAR only” policy can-
not be accepted in perspective of cost-effectiveness in Korea 
and which strategy to choose, open or endovascular, in AAA 
treatment should be individualized. Further research is required 
to determine the ideal indication of EVAR in terms of patient’s 
age, expected follow-up period after EVAR, costs for EVAR per 
se and follow-up with reintervention.
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